-
•Beijing R&D HQ
•Completed series angel financing
-
•1st mAb products SG001 received IND
•approval from NMPA
•Partnered with CSPC
•Complete Series A financing
-
•SG001 first in human study Completed series A+ financing
-
•1st fusion protein product SG404 received IND approval from NMPA
•CNBG SUMGEN founded, a joint venture between Sumgen and SinoPharm CGBN
•Completed series B financing
-
•SG301 IND approval by NMPA and 1st in human
•Completed series B financing
-
•SG1408 IND approval by NMPA
•SG1906 IND approval by FDA
-
•SG301 yielded positive clinical results
•SG001 BLA submitted and granted for conditional approval
•SG301SC the subcutaneous injection IND approval by NMPA for autoimmune disease
•SG1827 IND and 1st in human
•SG2918 IND approval by NMPA
-
•Selected for the "Hangzhou Quasi-Unicorn Enterprise" list again
•The first subject has been dosed in the Phase III clinical trial of the innovative drug SG301 injection
•Enlonstobart Injection (Brand Name: Enshuxin®) has been approved for launch
